2024-06-14T11:17:57.153Z
CUPID
CUPID
Prostate cancer
A phase I, single centre, open-label study of TLX592 to assess the safety and tolerability, pharmacokinetics, biodistribution and radiation dosimetry in patients diagnosed with prostate cancer.
A phase I, single centre, open-label study of TLX592 to assess the safety and tolerability, pharmacokinetics, biodistribution and radiation dosimetry in patients diagnosed with prostate cancer.
Trial overview
Clinical Area
Theranostics
Disease / Condition
Prostate Cancer
Study Phase
I
Trial Identifiers
NCT04726033
GenesisCare Location(s)
Principal Investigator(s)